0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Special Feature |

Picture of the Month—Diagnosis FREE

[+] Author Affiliations

Section Editor: Samir S. Shah, MD

More Author Information
Arch Pediatr Adolesc Med. 2010;164(5):490. doi:10.1001/archpediatrics.2010.53-b.
Text Size: A A A
Published online

DENOUEMENT AND DISCUSSION: LISCH NODULES, ECTROPION UVEAE, AND OPTIC PATHWAY GLIOMA (JUVENILE PILOCYTIC ASTROCYTOMA) DUE TO NEUROFIBROMATOSIS TYPE 1

This patient had iris Lisch nodules which, combined with an optic pathway glioma, are diagnostic for neurofibromatosis type 1 (NF1). Ectropion uveae is a rare congenital anomaly of the iris and is associated with NF1 more commonly than other syndromes.1

Neurofibromatosis type 1 is inherited in an autosomal dominant pattern, though up to 50% of new diagnoses of NF1 arise from spontaneous mutations. The incidence is as high as 1 in 3000 births; all races and sexes are affected equally.2Diagnosis of NF1 is based on well-established criteria that include at least 2 of the following: 6 or more café-au-lait macules that are 0.5 cm or larger (>1.5 cm after puberty), 2 or more Lisch nodules (benign iris hamartomas), 2 or more neurofibromas of any type or 1 or more plexiform neurofibromas, axillary or inguinal freckling, optic pathway glioma, dysplasia or thinning of long bone cortex or dysplasia of the sphenoid bone, or a first-degree relative with NF1.

Lisch nodules are round, elevated, benign hamartomas of the iris that are most frequently located on the inferior portion of the iris.3Lisch nodules can be distinguished from normal patches of iris pigmentation and iris nevi owing to their round and raised appearance, which is best appreciated with binocular viewing through a slitlamp microscope. Most (63%-92%) patients with NF1 are reported to have Lisch nodules.3,4They are not immediately present at birth and are found more commonly in postpubertal patients.3The number and size of Lisch nodules have no association with the frequency or severity of NF1-associated complications.

Ectropion uveae is a rare anomaly of the iris that causes the pupil to appear misshapen. The eversion of the pigmented posterior epithelium of the iris at the pupillary margin causes this appearance. Though some cases are acquired as a consequence of chronic inflammation, congenital forms are more typically associated with other conditions including Prader-Willi syndrome, facial hemihypertrophy, and, most commonly, NF1.1,5Congenital and acquired ectropion uveae are frequently associated with glaucoma and thus require close observation.

Low-grade gliomas (ie, juvenile pilocytic astrocytomas or fibrillary astrocytomas) involving the optic nerve, optic chiasm, optic tract, optic radiation, and hypothalamus are termed optic pathway gliomas and occur in up to 20% of children with NF1.6,7Up to half of the children with NF1-related optic pathway gliomas can experience vision loss as a result of their glioma.68Neurofibromatosis type 1–related optic pathway gliomas rarely cause new vision loss in children older than 8 years.9Given that not all children with NF1 will lose vision from their optic pathway gliomas, treatment with chemotherapy is typically deferred until vision loss occurs.

Expert consensus has provided ophthalmologic follow-up and treatment guidelines for children with NF1.9All children with NF1 should have a complete ophthalmologic examination by a pediatric ophthalmologist or neuro-ophthalmologist every year until 8 years of age. After 8 years of age, examinations can occur every 2 years. However, if the child is found to have an optic pathway glioma, examinations should occur every 6 months until 8 years of age, then yearly thereafter.9All examinations should include a quantitative assessment of visual acuity and color vision. When a reliable visual acuity measurement cannot be obtained in a child with NF1, most commonly owing to lack of cooperation, brain magnetic resonance imaging may be indicated.

Children observed to have Lisch nodules or ectropion uveae should be referred to a pediatric ophthalmologist or neuro-ophthalmologist, preferably with experience in caring for children with NF1. Additionally, children discovered to have a glioma of the optic pathway should be examined for the presence of NF1.

Return to Quiz Case.

Correspondence:Robert A. Avery, DO, Division of Ophthalmology, Children's Hospital of Philadelphia, 34th and Civic Center Boulevard, Ninth Floor Main Building, Philadelphia, PA 19104-4399 (averyr@email.chop.edu).

Accepted for Publication:January 11, 2010.

Author Contributions:Study concept and design: Avery and Liu. Acquisition of data: Avery. Analysis and interpretation of data: Avery and Liu. Drafting of the manuscript: Avery. Critical revision of the manuscript for important intellectual content: Avery and Liu. Administrative, technical, and material support: Avery. Study supervision: Liu.

Financial Disclosure:None reported.

Funding Support:This article was supported by the National Institutes of Health/National Eye Institute Loan repayment program and grant 1T32NS061779-01 for the Neurologic Clinical Epidemiology Training Program (principal investigator, Laura Balcer, MD) from the National Institutes of Health (Dr Avery).

Disclaimer:The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Ritch  RForbes  MHetherington  J  JrHarrison  RPodos  SM Congenital ectropion uveae with glaucoma. Ophthalmology 1984;91 (4) 326- 331
PubMed Link to Article
Lynch  TMGutmann  DH Neurofibromatosis 1. Neurol Clin 2002;20 (3) 841- 865
Link to Article
Nichols  JCAmato  JEChung  SM Characteristics of lisch nodules in patients with neurofibromatosis type 1. J Pediatr Ophthalmol Strabismus 2003;40 (5) 293- 296
PubMed
Lewis  RARiccardi  VM Von Recklinghausen neurofibromatosis: incidence of iris hamartoma. Ophthalmology 1981;88 (4) 348- 354
PubMed Link to Article
Trovó-Marqui  ABGoloni-Bertollo  EMTeixeira  MFTajara  EH Presence of the R1748X mutation of the NF1 gene in a Brazilian patient with ectropion uveae. Ophthalmic Res 2004;36 (6) 349- 352
PubMed Link to Article
Listernick  RCharrow  JGreenwald  MMets  M Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr 1994;125 (1) 63- 66
PubMed Link to Article
Listernick  RLouis  DNPacker  RJGutmann  DH Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 1997;41 (2) 143- 149
PubMed Link to Article
Balcer  LJLiu  GTHeller  G  et al.  Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging. Am J Ophthalmol 2001;131 (4) 442- 445
PubMed Link to Article
Listernick  RFerner  FELiu  GTGutmann  DH Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 2007;61 (3) 189- 198
PubMed Link to Article

Figures

Tables

References

Ritch  RForbes  MHetherington  J  JrHarrison  RPodos  SM Congenital ectropion uveae with glaucoma. Ophthalmology 1984;91 (4) 326- 331
PubMed Link to Article
Lynch  TMGutmann  DH Neurofibromatosis 1. Neurol Clin 2002;20 (3) 841- 865
Link to Article
Nichols  JCAmato  JEChung  SM Characteristics of lisch nodules in patients with neurofibromatosis type 1. J Pediatr Ophthalmol Strabismus 2003;40 (5) 293- 296
PubMed
Lewis  RARiccardi  VM Von Recklinghausen neurofibromatosis: incidence of iris hamartoma. Ophthalmology 1981;88 (4) 348- 354
PubMed Link to Article
Trovó-Marqui  ABGoloni-Bertollo  EMTeixeira  MFTajara  EH Presence of the R1748X mutation of the NF1 gene in a Brazilian patient with ectropion uveae. Ophthalmic Res 2004;36 (6) 349- 352
PubMed Link to Article
Listernick  RCharrow  JGreenwald  MMets  M Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr 1994;125 (1) 63- 66
PubMed Link to Article
Listernick  RLouis  DNPacker  RJGutmann  DH Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 1997;41 (2) 143- 149
PubMed Link to Article
Balcer  LJLiu  GTHeller  G  et al.  Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging. Am J Ophthalmol 2001;131 (4) 442- 445
PubMed Link to Article
Listernick  RFerner  FELiu  GTGutmann  DH Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 2007;61 (3) 189- 198
PubMed Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections